US-based PerkinElmer has introduced its automated genetic disorder screening system in China, after receiving market authorization from the China Food and Drug Administration (CFDA) for its Genetic Screening Processor (GSP) instrument and GSP Neonatal hTSH reagent kit.
The GSP is a fully automated and high throughput analyzer, which examines neonatal dried blood spot samples to detect potentially life-threatening conditions in newborn babies.
The GSP Neonatal hTSH reagent kit has been specifically designed to detect congenital hypothyroidism.
PerkinElmer Asia-Pacific diagnostics general manager and vice-president Johnson Zhang said: "We are committed to developing innovative solutions to help newborn screening labs in China respond to rising birth rates and expand access to testing for serious health risks in newborn babies.
"As China seeks to improve the efficiency of newborn screening and reduce false positive and false negative rates, our advanced detection technologies are designed to deliver highly reliable results for better outcomes."
According to the company, the GSP instrument can perform a wide range of disorders using its dried blood spot assays on a single platform.
The GSP instrument can be expanded to help laboratories to automate every stage of an assay, from specimen reception to results reporting.
PerkinElmer’s informatics software also offers automation of the newborn screening process through allowing integration of additional assays, analytical instruments and punchers onto the GSP’s platform.